Caribou Biosciences (Caribou Biosciences) Debt-to-Equity : 0.08 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Caribou Biosciences Debt-to-Equity?

Caribou Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.26 Mil. Caribou Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $25.90 Mil. Caribou Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $343.29 Mil. Caribou Biosciences's debt to equity for the quarter that ended in Mar. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Caribou Biosciences's Debt-to-Equity or its related term are showing as below:

CRBU' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.07 Med: 0.08 Max: 0.1
Current: 0.08

During the past 5 years, the highest Debt-to-Equity Ratio of Caribou Biosciences was 0.10. The lowest was -0.07. And the median was 0.08.

CRBU's Debt-to-Equity is ranked better than
64.13% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs CRBU: 0.08

Caribou Biosciences Debt-to-Equity Historical Data

The historical data trend for Caribou Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caribou Biosciences Debt-to-Equity Chart

Caribou Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.07

0.09

0.07

Caribou Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial													0.10	0.10	0.07	0.07	0.08

Competitive Comparison of Caribou Biosciences's Debt-to-Equity

For the Biotechnology subindustry, Caribou Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caribou Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Caribou Biosciences's Debt-to-Equity falls into.

Caribou Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Caribou Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.2	+	25.908)	/	368.401
	=	0.07

Caribou Biosciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.264	+	25.895)	/	343.289
	=	0.08

Caribou Biosciences (NAS:CRBU) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Caribou Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Caribou Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Caribou Biosciences (Caribou Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caribou Biosciences Inc (NAS:CRBU) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 7th Street, Suite 105, Berkeley, CA, USA, 94710

Website

https://www.cariboubio.com

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Executives

Syed Ali-aamir Rizvi	officer: Chief Medical Officer	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ryan Fischesser	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Steven Kanner	officer: See Remarks	CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
David Lee Johnson	director	C/O GLOBAL BLOOD THERAPEUTICS, 171 OYSTER POINT BLVD, STE. 300, SAN FRANCISCO CA 94080
Barbara G Mcclung	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ruhi Ahmad Khan	officer: Chief Business Officer	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Dara Richardson-heron	director	C/O CARIBOU BIOSCIENCES, INC., 29, BERKELEY CA 94710
Ran Zheng	director	2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Nancy Whiting	director	2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
Natalie Sacks	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Rachel E. Haurwitz	director, officer: See Remarks	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Andrew Guggenhime	director	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Jason O'byrne	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710